Axcella to Report Second Quarter 2020 Financial Results and Hold Conference Call on August 5, 2020
August 03 2020 - 8:00AM
Business Wire
Conference call to take place at 8:30 a.m.
ET
Axcella (Nasdaq: AXLA), a clinical-stage
biotechnology company focused on leveraging endogenous metabolic
modulators (EMMs) to pioneer a new approach for treating complex
diseases and improving health, today announced that it plans to
report its second quarter financial results and other business
updates on August 5, 2020. The company will host a conference call
at 8:30 a.m. ET that morning.
The conference call webcast and accompanying slides will be made
available shortly before the start of the call on the company’s
website at www.axcellahealth.com in the Investors & News
section. To access the call via telephone, please dial (866)
652-5200 (U.S. toll free) or (412) 317-6060 (international) five
minutes prior to the start time. For those unable to listen in
live, a webcast archive will be available on the company’s website
for 30 days following the call.
Internet Posting of Information Axcella uses its website,
www.axcellahealth.com, as a means of disclosing material nonpublic
information and for complying with its disclosure obligations under
Regulation FD. Such disclosures will be included on the company’s
website in the “Investors and News” section. Accordingly, investors
should monitor such portions of the company’s website, in addition
to following its press releases, SEC filings and public conference
calls and webcasts.
About Axcella Axcella is a clinical-stage biotechnology
company focused on leveraging endogenous metabolic modulators
(EMMs) to pioneer a new approach for treating complex diseases and
improving health. The company’s product candidates are comprised of
EMMs and their derivatives that are engineered in distinct
combinations and ratios to simultaneously impact multiple
biological pathways. Axcella’s pipeline includes lead therapeutic
candidates for non-alcoholic steatohepatitis (NASH) and the
reduction in risk of overt hepatic encephalopathy (OHE) recurrence.
Additional muscle- and blood-related programs are in earlier-stage
development. For more information, please visit
www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200803005168/en/
Company/Investor Contact Jason Fredette
jfredette@axcellahealth.com 857.320.2236
Media Contact Azeem Zeekrya HDMZ azeem.zeekrya@hdmz.com
312-506-5244
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Sep 2023 to Sep 2024